Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125

Rebelo, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 De Angelis, 2014, Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study, Lancet Oncol, 15, 23, 10.1016/S1470-2045(13)70546-1 Cliby, 2015, Ovarian cancer in the United States: contemporary patterns of care associated with improved survival, Gynecol Oncol, 136, 11, 10.1016/j.ygyno.2014.10.023 Azzam, 2013, Evaluation of HE4 as an extra biomarker to CA125 to improve detection of ovarian carcinoma: is it time for step forward?, Arch Gynecol Obstet, 288, 167, 10.1007/s00404-013-2722-2 Park, 2011, Diagnostic performance of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases, Clin Biochem, 44, 884, 10.1016/j.clinbiochem.2011.04.011 Nosov, 2009, Validation of serum biomarkers for detection of early-stage ovarian cancer, Am J Obstet Gynecol, 200, 639, 10.1016/j.ajog.2008.12.042 Wei, 2015, Chin J Cancer Res, 27, 38 Vallius, 2017, Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer, Tumour Biol, 39, 10.1177/1010428317691189 Shen, 2016, Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer, Tumour Biol, 37, 14765, 10.1007/s13277-016-5335-0 Langmár, 2011, HE4 – a novel promising serum marker in the diagnosis of ovarian carcinoma, Eur J Gynaecol Oncol, 32, 605 Lee, 2017, Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer, J Obstet Gynaecol Res, 43, 220, 10.1111/jog.13181 Innao, 2016, Does human epididymis protein 4 (HE4) have a role in prediction of recurrent epithelial ovarian cancer, Asian Pac J Cancer Prev, 17, 4483 Steffensen, 2016, Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer, Oncol Lett, 11, 3967, 10.3892/ol.2016.4533 Zhang, 2004, Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer, Cancer Res, 64, 5882, 10.1158/0008-5472.CAN-04-0746 Liu, 2007, Reduced transthyretin expression in sera of lung cancer, Cancer Sci, 98, 1617, 10.1111/j.1349-7006.2007.00576.x Schweigert, 2005, Transthyretin, a biomarker for nutritional status and ovarian cancer, Cancer Res, 65, 1114, 10.1158/0008-5472.1114.65.3 Kozak, 2005, Characterization of serum biomarkers for detection of early stage ovarian cancer, Proteomics, 5, 4589, 10.1002/pmic.200500093 Kozak, 2005, Characterization of serum biomarkers for detection of early stage ovarian cancer, Proteomics, 5, 4589, 10.1002/pmic.200500093 Kim, 2012, Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers, PLoS ONE, 7, e44960, 10.1371/journal.pone.0044960 Farias-Eisner, 2010, Validation of serum biomarkers for detection of early- and late-stage endometrial cancer, Am J Obstet Gynecol, 202, 10.1016/j.ajog.2009.07.049 Moore, 2008, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecol Oncol, 108, 402, 10.1016/j.ygyno.2007.10.017